VAL.L实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (1 Jul 2024 @ 16:12):
Our systems believe the stock currently is overvalued by -0.15% compare to its pairs and should correct downwards.

Stats
今日成交量	154 542
平均成交量	1.86M
市值	4.17M
EPS	£-0.00980 ( Q4 \| 2023-12-31 )
下一个收益日期	( £0 ) 2024-08-21
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-1.570 (Sector) 0 (Industry) 0
ATR14	£0.0990 (3.14%)

AMYT.L -11.73%

APH.L 0.39%

AVCT.L -0.27%

AZN.L -0.40%

BMK.L 7.59%

BVXP.L -2.16%

C4XD.L 27.32%

CIR.L 0.00%

CLIN.L 0.11%

DEST.L -2.51%

DPH.L 0.05%

EAH.L 3.49%

ERGO.L 0.15%

ETX.L -6.74%

EVG.L 2.25%

FAB.L -1.59%

FARN.L -5.08%

FUM.L 0.27%

GDR.L 1.10%

GNS.L 1.45%

GSK.L -0.52%

HCM.L -0.36%

HEMO.L 0.23%

HIK.L -0.58%

IMM.L -1.15%

INDV.L 0.32%

IXI.L -5.25%

MTPH.L 1 794.74%

MXCT.L -2.17%

N4P.L -4.71%

NCYT.L -2.42%

NFX.L -4.71%

OBD.L 0.92%

OKYO.L -24.32%

ONC.L 0.45%

OPTI.L -3.75%

OVB.L -2.22%

OXB.L 2.58%

PRM.L -4.82%

PRTC.L 0.22%

PYC.L -6.25%

REDX.L 31.58%

RENE.L -2.17%

SAR.L 7.00%

SCLP.L -1.86%

SLN.L -0.93%

SNG.L 3.48%

STX.L 2.70%

TILS.L 8.33%

TRX.L -1.15%

VAL.L 0.00%

VEC.L 0.00%

相关性 (AI algo v.1.1b): Overvalued: -0.15% £3.15 paired level. (算法实时跟踪最相关股票的变化并提供即时更新)

ValiRx PLC 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

ValiRx PLC 财务报表

Annual	2023
营收:	£9 600.00
毛利润:	£-246 043 (-2 562.95 %)
EPS:	£-0.0201

FY	2023
营收:	£9 600.00
毛利润:	£-246 043 (-2 562.95 %)
EPS:	£-0.0201

FY	2022
营收:	£0
毛利润:	£-224 268 (0.00 %)
EPS:	£-0.0311

FY	2021
营收:	£0.00
毛利润:	£0.00 (0.00 %)
EPS:	£-0.0401

Financial Reports:

No articles found.

ValiRx PLC Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

ValiRx PLC

ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a small molecule that has completed Phase I/II trials for the treatment of prostate cancer and other hormone associated solid tumours comprising breast and ovarian cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of non-small cell lung cancer. Its drug candidates also comprise VAL301, a peptide ingredient that in pre-clinical development for the treatment of women with endometriosis; and BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19. ValiRx plc was incorporated in 2000 and is based in Hatfield, the United Kingdom.